- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02608437
A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients (NIBIT-M4)
A Phase 1b, Open-label, Dose Escalation Study Investigating Different Doses of SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Epigenetic alterations play a pivotal role in cancer development and progression. Pharmacologic reversion of such alterations is feasible, and second generation "epigenetic drugs" are in development and have demonstrated to possess significant immunomodulatory properties. This knowledge, together with the availability of new and highly effective immuno-therapeutic agents including immune check-point(s) blocking monoclonal antibodies, allows us to plan for highly innovative proof-of-principle combination studies that will likely open the path to more effective anti-cancer therapies.
Targeting immune check-point(s) with immunomodulatory monoclonal antibody (mAb) is a novel and rapidly evolving strategy to treat cancer, that is rapidly spreading to different tumor histologies. The prototype approach of this therapeutic modality relies on the inhibition of negative signals delivered by CTLA-4 expressed on T lymphocytes. CTLA-4 blockade has profoundly changed the therapeutic landscape of metastatic melanoma (MM), significantly improving the survival of MM patients; however, objective clinical responses are limited, and only a minority of patients achieves long-term disease control.1 Therefore, several combination approaches are being explored to improve the efficacy of CTLA-4 blockade. Along this line, based on the preclinical evidence the investigators gained on the broad immunomodulatory activity of SGI-110, the exploratory phase 1 combination study NIBIT-M4 has been designed to provide proof-of-concept evidence to the immunologic and clinical efficacy of CTLA-4 blockade combined with DNA-HypomethylatingAgent (DHA). Progressing Stage III or Stage IV MM patients, amenable to serial tumor biopsies will be enrolled in the study.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Anna Maria Di Giacomo, PhD,MD
- Phone Number: +390577586305
- Email: a.m.digiacomo@ao-siena.toscana.it
Study Contact Backup
- Name: Michele Maio, PhD,MD
- Phone Number: +390577586335
- Email: mmaiocro@gmail.com
Study Locations
-
-
-
Siena, Italy, 53100
- Recruiting
- Medical Oncology and Immunotherapy Unit, University Hospital of Siena
-
Contact:
- Anna Maria Di Giacomo, PhD, MD
- Phone Number: +390577586305
- Email: a.m.digiacomo@ao-siena.toscana.it
-
Contact:
- Giovanni Amato, PhD
- Phone Number: +390577586326
- Email: dataman.immonco@ao-siena.toscana.it
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Willing and able to give written informed consent
- Unresectable Stage III or Stage IV melanoma with measurable lesions by CT or MRI per mWHO/irRC criteria, that can be amenable to biopsy
- Previously treated or untreated; prior therapy may include chemotherapy or targeted therapy for metastatic disease (i.e., BRAF and/or MAP-ERK kinase (MEK) inhibitor). Prior adjuvant interferon is permitted
- Subjects with Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
- 4 weeks or greater since last treatment
- Must have recovered from any acute toxicity associated with prior therapy
- Life expectancy greater than 16 weeks
- Negative screening tests for HIV, Hepatitis B, and Hepatitis C
- Women of child-bearing potential must not be pregnant or breastfeeding, must have a negative pregnancy test at Screening and all men must be practicing two medically acceptable methods of birth control. Men should not father a child while receiving treatment with SGI-110 + ipilimumab, and for 2 months following completion of treatment. Men with female partners of childbearing potential should use effective contraception during this time
Exclusion Criteria:
- Subjects with any contraindications for ipilimumab
- Subjects with active brain metastases or leptomeningeal metastases
- Subjects with metastatic uveal melanoma
- Subjects with active, known or suspected autoimmune disease
- Subjects with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of treatment
- Subjects with symptomatic effusions on account of pleural, pericardial metastases of melanoma
- Prior treatment with an anti-Programmed Death receptor-1 (PD-1), anti-Programmed Death-1 ligand-1 (PD-L1), anti-PD-L2, or anti-CTLA-4 antibody
- Subjects who had major surgery or radiation therapy within 21 days of starting treatment
- Subjects who are unable to return for follow-up visits as required by this study
Other Exclusion Criteria:
- Prisoners or subjects who are involuntarily incarcerated
- Subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SGI-110 and Ipilimumab
SGI-110 in combination with Ipilimumab
|
SGI-110: start at 30 mg/m2 s.c. on W0, 3, 6, 9 Day 1 - 5 q21 days.
Dose level -1: 15 mg/m2; dose level +1: 45 mg/m2
ipilimumab: 3 mg/Kg i.v. over 90 minutes on W1, 4, 7 and 10 for a total of 4 cycles.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose (MTD) of SGI-110 in combination with ipilimumab
Time Frame: the first 3 weeks of treatment
|
The primary objective is to determine the MTD of SGI-110 in combination with ipilimumab in 21 day cycles in melanoma patients.
Endpoints related to this objective include an evaluation of Dose Limiting Toxicity(s).
The MTD evaluation will be based on the DLT evaluable population.
|
the first 3 weeks of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immune-related Disease Control Rate (irDCR)
Time Frame: weeks 24
|
Immune-related Disease Control Rate (irDCR) is the proportion of treated subjects with an immune-related Best Overall Responce (ir-BOR) of confirmed irCR, confirmed irPR or irSD.
|
weeks 24
|
Immune-related Objective Response Rate (irORR)
Time Frame: weeks 24
|
Immune-related Objective Response Rate (irORR) is the proportion of treated subjects with a irBOR of confirmed irCR or confirmed irPR.
|
weeks 24
|
Immune-related Time to Response (irTTR)
Time Frame: weeks 24
|
Immune-related Time to Response (irTTR) is defined as the time from first dosing date until the measurement criteria are first met for overall response of irPR or irCR (whichever status comes first, and provided it is subsequently confirmed).
|
weeks 24
|
Immune-related Duration of Response (irDoR)
Time Frame: 2 years
|
Immune-related Duration of Response (irDoR) for the subjects whose irBOR is irCR or irPR will be defined as the time between the date of response of confirmed irCR or confirmed irPR (whichever occurs first) and the date of irPD or death (whichever occurs first).
The onset of a confirmed irCR or irPR is determined by the initial assessment of response, not by the confirmatory assessment.
Note that if an assessment of irPR occurs before confirmation of irCR, the duration of immune-related response endpoint will not begin at the time that the irBOR of irCR is shown but rather at the earlier time-point showing irPR.
For subjects who remain alive and have not progressed following response, irDoR will be censored on the date of last evaluable Tumor Assessment.
|
2 years
|
Immune-related progression free survival (irPFS)
Time Frame: 2 years
|
Immune-related progression free survival (irPFS) per irRC will be defined as the time between the date of randomization and the date of progression per irRC or death, whichever occurs first.
A subject who dies without reported progression per irRC will be considered to have progressed on the date of death.
For those subjects who remain alive and have not progressed, irPFS will be censored on the date of last evaluable Tumor Assesment.
For those subjects who remain alive and have no recorded post baseline Tumor Assessment, irPFS will be censored on the day of last clinical evaluation.
|
2 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phenotypic/epigenetic profile of tumor samples and peripheral blood mononuclear cells
Time Frame: 2 years
|
Changes in the immune phenotype/epigenetic profile of neoplastic cells and of immune cells.
|
2 years
|
humoral immune responses induced by treatment
Time Frame: 2 years
|
Changes in the humoral and cellular immune responses induced by treatment will be investigated utilizing standardized and validated techniques.
|
2 years
|
Maximum Plasma Concentration [Cmax] of of SGI-110 and decitabine.
Time Frame: 24 hours
|
Plasma samples will be prepared from blood drawn at the following time-points: Cycle 1, Day 1: pre-dose, 15 min, 30 min, 60 min, 90 min, 2 hr, 4 hr, 6 hr and 8 hr post-dose.
|
24 hours
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Anna Maria Di Giacomo, PhD,MD, Medical Oncology and Immunotherapy Unit, University Hospital of Siena
Publications and helpful links
General Publications
- Maio M, Di Giacomo AM, Robert C, Eggermont AM. Update on the role of ipilimumab in melanoma and first data on new combination therapies. Curr Opin Oncol. 2013 Mar;25(2):166-72. doi: 10.1097/CCO.0b013e32835dae4f.
- Covre A, Coral S, Di Giacomo AM, Taverna P, Azab M, Maio M. Epigenetics meets immune checkpoints. Semin Oncol. 2015 Jun;42(3):506-13. doi: 10.1053/j.seminoncol.2015.02.003. Epub 2015 Feb 14.
- Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007 Jan 1;109(1):52-7. doi: 10.1182/blood-2006-05-021162. Epub 2006 Aug 1.
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Nevi and Melanomas
- Melanoma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Ipilimumab
- Guadecitabine
Other Study ID Numbers
- NIBIT-M4
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Melanoma
-
Mohammed M MilhemGenentech, Inc.TerminatedMelanoma | Metastatic Melanoma | BRAF-mutated Metastatic Melanoma | V600EBRAF-mutated Metastatic MelanomaUnited States
-
Delcath Systems Inc.Active, not recruitingMetastatic Uveal Melanoma | Metastatic Ocular MelanomaUnited States
-
National Cancer Institute (NCI)TerminatedMetastatic Uveal Melanoma | Metastatic Ocular MelanomaUnited States
-
MorphotekTerminatedMelanoma | Metastatic Melanoma | Advanced Melanoma | Malignant Metastatic MelanomaUnited States
-
GlaxoSmithKlineWithdrawnCancer | Metastatic Uveal Melanoma | GNA11 Mutation-positive Metastatic Melanoma | GNAQ Mutation-positive Metastatic Melanoma
-
Elizabeth DavisBristol-Myers SquibbTerminatedMetastatic Melanoma | Advanced Melanoma | Metastatic Melanoma Stratified by MHC-II ExpressionUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingMetastatic Melanoma | Metastatic Uveal Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterAmazon.com Services LLCRecruitingAnatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC... and other conditionsUnited States
-
Provectus Biopharmaceuticals, Inc.Active, not recruitingMetastatic Colorectal Cancer | Hepatocellular Carcinoma | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Melanoma | Metastatic Uveal Melanoma | Metastatic Pancreatic Cancer | Metastatic Colon Cancer | Metastatic Ocular Melanoma | Cancer Metastatic to the LiverUnited States
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Cutaneous Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Recurrent Cutaneous Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Recurrent Mucosal Melanoma | Metastatic Mucosal Melanoma | Non-Cutaneous Melanoma | Metastatic Non-Cutaneous Melanoma | Recurrent Non-Cutaneous...United States, Canada, Ireland
Clinical Trials on SGI-110
-
Astex Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Myeloid Dysplastic SyndromeUnited States, Taiwan, Korea, Republic of, Canada, Spain, Japan, Italy, Austria, Denmark
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHigh Risk Myelodysplastic SyndromeUnited States
-
Weill Medical College of Cornell UniversityAstex Pharmaceuticals, Inc.CompletedMyeloproliferative NeoplasmsUnited States
-
Astex Pharmaceuticals, Inc.CompletedHepatocellular CarcinomaUnited States, United Kingdom, Canada
-
Otsuka Pharmaceutical Co., Ltd.Completed
-
Groupe Francophone des MyelodysplasiesUnknownAcute Myeloid Leukemia | Myelodysplastic SyndromesFrance
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic SyndromeUnited States
-
Groupe Francophone des MyelodysplasiesAstex Pharmaceuticals, Inc.Completed
-
Shadia Jalal, MDAstex Pharmaceuticals, Inc.; Indiana University School of MedicineCompletedSmall Cell Lung Cancer | Extensive-stage Small Cell Lung CancerUnited States
-
Ajjai Alva, MDAstraZeneca; Big Ten Cancer Research ConsortiumActive, not recruitingKidney Cancer | Clear Cell Renal Cell Carcinoma | Advanced Kidney CancerUnited States